Thousands of Scots are being sought for a trial to find out if heart attack patients over the age of 75 could benefit from treatment more commonly given to younger people. The British Heart Foundation say little research has been carried out to look at how best to treat older patients despite the fact that 50% of heart attacks happen in patients aged 72 and over....
Lonza’s integrated development and manufacturing site for biopharmaceutical liquid-filled hard capsules has new anti-counterfeiting security capabilities in place and is now in full compliance with EU and U.S. regulatory requirements for serialization. With increasing threats to patient safety from counterfeited and diverted pharmaceuticals, new rules for serialization in more than 40 countries are being implemented to secure the world’s pharmaceutical supply chain. To read the full...
CMAC (Continuous Manufacturing and Advanced Crystallisation), a pre-competitive consortium led by the University of Strathclyde to accelerate progress in pharmaceutical manufacturing, announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche. CMAC is a world-class national centre in advanced pharmaceutical manufacturing, focusing on accelerating the adoption of continuous manufacturing for the production of medicines with a...
LMTX, a drug, which destroys the tau proteins that kill neurons, can dramatically slow mental decline in just nine months has began human trials. In some patients the rate of decline returned to that seen in elderly people with healthy brains, said scientists. The international study of 800 participants found a 4mg pill, taken twice daily, achieved this result. The drug was invented by Professor Claude Wischik...
NuCana, an Edinburgh-based medical firm has raised almost £75 million by floating on the stock market. NuCana develops techniques to boost the effectiveness of chemotherapy. The funds will be used to further clinical trials and expand the business in Edinburgh creating more jobs in the area. To read the full article, click here.
Exscientia Ltd received €15 million investment from Evotec AG giving them a minority stake. Exscientia is focused on Artificial Intelligence (AI) driven drug discovery and design. Evotec and Exscientia have worked in partnership since early 2016, the success of this relationship is the basis of this investment allowing further advances in their immuno-oncology therapeutic research in the future. To read the full article, click here.